Emcure Pharma is acquiring the remaining stake in Gennova Biopharmaceuticals. This move simplifies ownership and sharpens strategic focus for the subsidiary. Gennova will now be led by Samit Mehta for its next growth phase. The company will continue leveraging its biomanufacturing platforms for new products. Gennova's former CEO Sanjay Singh has divested its mRNA business.

Emcure's Gennova transfers its mRNA business to Immunoscript Life Science for ₹139 crore, focusing on core biotech operations.

Emcure Pharmaceuticals acquires full control of Gennova Biopharma with a ₹232 crore stake purchase, enhancing its biologics focus.

Emcure Pharma is acquiring the remaining stake in Gennova Biopharmaceuticals. This move simplifies ownership and sharpens strategic focus for the subsidiary. Gennova will now be…